---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009643"
form_type: "8-K"
ticker: null
cik: "0001722964"
company_name: "Y-mAbs Therapeutics, Inc."
filed_at: "2024-07-01T23:59:59+00:00"
generated_at: "2026-06-01T00:05:06.547099+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Y-mAbs names Peter Pfreundschuh CFO; outgoing CFO Bo Kruse to assist transition to July 31

## Summary
- Peter Pfreundschuh appointed CFO and Treasurer effective June 28, 2024; succeeds Bo Kruse who will assist transition through July 31, 2024.
- Base salary $500,000; eligible for annual cash bonus up to 45% of base; receives initial option to purchase 170,000 shares and 46,000 RSUs.
- Pfreundschuh previously CFO at Voyager, Frequency, UroGen, Sucampo; earlier roles at J&J, AstraZeneca, Ernst & Young.
- Company highlights commercial traction with DANYELZA and advancement of SADA-PRIT radioimmunotherapy platform.

## SEC filing metadata
- accession: 0001558370-24-009643
- form_type: 8-K
- cik: 0001722964
- company_name: Y-mAbs Therapeutics, Inc.
- filed_at: 2024-07-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1722964/000155837024009643/0001558370-24-009643-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1722964/000155837024009643/ymab-20240627x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009643
- JSON: https://secwatch.observer/filing/0001558370-24-009643.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009643.txt

## Key facts
- Executive change
  Bo Kruse departed as Chief Financial Officer and Treasurer at Y-mAbs Therapeutics, Inc..
  - Action: departing
  - Role: Chief Financial Officer and Treasurer
  source text: succeeded Bo Kruse, who is expected to remain available to the Company for a period of time following the conclusion of his employment on July 31, 2024, during which time Mr. Kruse will assist in the transition of his responsibilities and duties.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1722964/000155837024009643/0001558370-24-009643-index.htm
- Executive change
  Peter Pfreundschuh was appointed as Chief Financial Officer and Treasurer at Y-mAbs Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer and Treasurer
  source text: On June 27, 2024, the Board of Directors (the “Board”) of Y-mAbs Therapeutics, Inc. (the “Company”) appointed Peter Pfreundschuh to serve as the Company’s Chief Financial Officer and Treasurer, effective June 28, 2024 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1722964/000155837024009643/0001558370-24-009643-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.